J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Want to cut your energy bills? Here’s how five experts are doing it 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
REDWOOD CITY, Calif., March 17, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on Mar. 15, 2016, the compensation committee of the company’s board of directors granted 4 new employees options to purchase an aggregate of 10,400 shares of the company’s common stock with a per share exercise price of $12.94, the closing trading price on the grant date, and 5,200 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
